KR20080072761A - 프로테아좀 억제제와 함께 ｉｌ-6 길항제를 이용하는 방법 - Google Patents

프로테아좀 억제제와 함께 ｉｌ-6 길항제를 이용하는 방법 Download PDF

Info

Publication number
KR20080072761A
KR20080072761A KR1020087016043A KR20087016043A KR20080072761A KR 20080072761 A KR20080072761 A KR 20080072761A KR 1020087016043 A KR1020087016043 A KR 1020087016043A KR 20087016043 A KR20087016043 A KR 20087016043A KR 20080072761 A KR20080072761 A KR 20080072761A
Authority
KR
South Korea
Prior art keywords
antibody
disease
proteasome inhibitor
bortezomib
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087016043A
Other languages
English (en)
Korean (ko)
Inventor
모하메드 자카이
제프리 네메쓰
로버트 오르로우스키
Original Assignee
센토코 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센토코 인코포레이티드 filed Critical 센토코 인코포레이티드
Publication of KR20080072761A publication Critical patent/KR20080072761A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020087016043A 2005-12-09 2006-12-08 프로테아좀 억제제와 함께 ｉｌ-6 길항제를 이용하는 방법 Withdrawn KR20080072761A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09
US60/749,152 2005-12-09

Publications (1)

Publication Number Publication Date
KR20080072761A true KR20080072761A (ko) 2008-08-06

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087016043A Withdrawn KR20080072761A (ko) 2005-12-09 2006-12-08 프로테아좀 억제제와 함께 ｉｌ-6 길항제를 이용하는 방법

Country Status (15)

Country Link
US (1) US20090022726A1 (cg-RX-API-DMAC7.html)
EP (1) EP1954310A4 (cg-RX-API-DMAC7.html)
JP (1) JP2009518447A (cg-RX-API-DMAC7.html)
KR (1) KR20080072761A (cg-RX-API-DMAC7.html)
CN (1) CN101325969A (cg-RX-API-DMAC7.html)
AR (1) AR057227A1 (cg-RX-API-DMAC7.html)
AU (1) AU2006321610A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0619498A2 (cg-RX-API-DMAC7.html)
CA (1) CA2632732A1 (cg-RX-API-DMAC7.html)
EA (1) EA014675B1 (cg-RX-API-DMAC7.html)
IL (1) IL191694A0 (cg-RX-API-DMAC7.html)
NO (1) NO20082907L (cg-RX-API-DMAC7.html)
TW (1) TW200803895A (cg-RX-API-DMAC7.html)
WO (1) WO2007067976A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200805956B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163706A1 (ko) * 2014-04-25 2015-10-29 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
EP2030981B1 (en) 2004-05-10 2014-07-09 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
AR058135A1 (es) * 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) * 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
TWI438208B (zh) 2007-01-23 2014-05-21 中外製藥股份有限公司 抑制慢性排斥反應之藥劑
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
CA2728243C (en) * 2008-06-05 2020-03-10 Chugai Seiyaku Kabushiki Kaisha Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
EA201170527A1 (ru) * 2008-10-01 2011-10-31 Др. Редди'С Лабораторис Лтд. Фармацевтические композиции, включающие соединения бороновой кислоты
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
KR20160091440A (ko) * 2008-11-13 2016-08-02 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011006273A1 (en) 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
WO2011013786A1 (ja) * 2009-07-31 2011-02-03 Maeda Shin 癌の転移抑制剤
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
WO2011149051A1 (ja) 2010-05-28 2011-12-01 中外製薬株式会社 抗腫瘍t細胞応答増強剤
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
CN108030916A (zh) * 2015-07-03 2018-05-15 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions
EP3957324A4 (en) 2019-04-17 2023-02-08 Hiroshima University THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR20010080267A (ko) * 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
WO2004071404A2 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of il-6 antagonists in combination with steroids to enhance apoptosis
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015163706A1 (ko) * 2014-04-25 2015-10-29 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
EP1954310A2 (en) 2008-08-13
CA2632732A1 (en) 2007-06-14
TW200803895A (en) 2008-01-16
US20090022726A1 (en) 2009-01-22
AR057227A1 (es) 2007-11-21
EA200870029A1 (ru) 2008-10-30
ZA200805956B (en) 2009-10-28
IL191694A0 (en) 2008-12-29
AU2006321610A1 (en) 2007-06-14
EP1954310A4 (en) 2009-04-22
JP2009518447A (ja) 2009-05-07
WO2007067976A3 (en) 2008-02-14
EA014675B1 (ru) 2010-12-30
CN101325969A (zh) 2008-12-17
NO20082907L (no) 2008-08-26
WO2007067976A2 (en) 2007-06-14
BRPI0619498A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
KR20080072761A (ko) 프로테아좀 억제제와 함께 ｉｌ-6 길항제를 이용하는 방법
JP7411832B2 (ja) 抗ｔｇｆベータ抗体およびそれらの使用
US8383778B2 (en) IL-1 binding proteins
CN103596591B (zh) 骨关节炎和疼痛的治疗
JP5867706B2 (ja) 増殖誘導リガンド（ａｐｒｉｌ）に対する抗体
JP7315472B2 (ja) 炎症症状で使用するための抗ｉｌ－１ｒ３抗体
WO2008042611A2 (en) Method of using il6 antagonists with mitoxantrone for prostate cancer
US12209131B2 (en) Anti-IL1RAP antibody compositions
US20100196315A1 (en) IL-12/p40 BINDING PROTEINS
CZ296919B6 (cs) Farmaceutický prípravek pro lécení chronické revmatické artritidy
CA2728909A1 (en) Prostaglandin e2 binding proteins and uses thereof
CN102027015A (zh) 抗cxcr4抗体
JP2025525479A (ja) 抗ｉｌ１ｒａｐ抗体及び抗体薬物複合体を用いた疾患の治療方法
JP2023534191A (ja) 抗組織因子抗体を使用する炎症性疾患の治療法
JP6845237B2 (ja) 抗−ヒトｉｌ−３抗体、ｉｌ−３の高められた発現又はレベルに関連する疾患又は機能障害へのそれらの使用、及びヒトｉｌ−３の検出方法へのそれらの使用
MX2008007329A (en) Method of using il6 antagonists with proteasome inhibitors
MXPA00009315A (en) Inflammatory mediator antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080701

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid